Renaissance Technologies’s PDL BioPharma, Inc. PDLI Stock Holding History

Renaissance Technologies’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-7,598,131	Closed	-$23.9M	–	3894
2020 Q3	$23.9M	Sell	7,598,131 -696,118	-8%	-$2.22M	0.02%	651
2020 Q2	$24.1M	Buy	8,294,249 +70,718	+0.9%	+$224K	0.02%	715
2020 Q1	$23.2M	Buy	8,223,531 +52,900	+0.6%	+$171K	0.02%	690
2019 Q4	$26.5M	Sell	8,170,631 -1,193,654	-13%	-$3.47M	0.02%	844
2019 Q3	$20.2M	Buy	9,364,285 +343,203	+4%	+$917K	0.02%	952
2019 Q2	$28.3M	Sell	9,021,082 -607,418	-6%	-$1.97M	0.02%	771
2019 Q1	$35.8M	Buy	9,628,500 +553,000	+6%	+$1.87M	0.03%	674
2018 Q4	$26.3M	Sell	9,075,500 -98,454	-1%	-$270K	0.03%	728
2018 Q3	$24.1M	Sell	9,173,954 -514,400	-5%	-$1.26M	0.02%	818
2018 Q2	$22.7M	Buy	9,688,354 +39,500	+0.4%	+$110K	0.02%	846
2018 Q1	$28.4M	Sell	9,648,854 -635,600	-6%	-$1.73M	0.03%	733
2017 Q4	$28.2M	Sell	10,284,454 -847,332	-8%	-$2.6M	0.03%	732
2017 Q3	$37.7M	Buy	11,131,786 +427,386	+4%	+$1.19M	0.04%	559
2017 Q2	$26.4M	Sell	10,704,400 -1,332,354	-11%	-$3.06M	0.03%	696
2017 Q1	$27.3M	Sell	12,036,754 -838,946	-7%	-$1.86M	0.04%	619
2016 Q4	$27.3M	Sell	12,875,700 -597,154	-4%	-$1.67M	0.04%	595
2016 Q3	$45.1M	Buy	13,472,854 +907,200	+7%	+$2.88M	0.08%	311
2016 Q2	$39.5M	Sell	12,565,654 -158,700	-1%	-$529K	0.08%	338
2016 Q1	$42.4M	Buy	12,724,354 +2,378,795	+23%	+$7.42M	0.08%	294
2015 Q4	$36.6M	Buy	10,345,559 +1,349,405	+15%	+$5.65M	0.08%	297
2015 Q3	$45.3M	Sell	8,996,154 -2,536,600	-22%	-$14.5M	0.11%	202
2015 Q2	$74.2M	Sell	11,532,754 -438,800	-4%	-$2.94M	0.17%	102
2015 Q1	$84.2M	Buy	11,971,554 +200,554	+2%	+$1.45M	0.18%	101
2014 Q4	$90.8M	Sell	11,771,000 -1,974,892	-14%	-$15.6M	0.22%	71
2014 Q3	$103M	Buy	13,745,892 +849,138	+7%	+$7.88M	0.28%	47
2014 Q2	$125M	Buy	12,896,754 +1,037,570	+9%	+$9.25M	0.29%	45
2014 Q1	$98.5M	Buy	11,859,184 +193,830	+2%	+$1.66M	0.24%	65
2013 Q4	$98.5M	Buy	11,665,354 +73,400	+0.6%	+$619K	0.24%	74
2013 Q3	$92.4M	Sell	11,591,954 -396,600	-3%	-$3.19M	0.22%	81
2013 Q2	$92.6M	Buy	+11,988,554	New	+$93.5M	0.24%	76

Other funds holding PDLI

SPC

Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

CCM

Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return

Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Renaissance Technologies's PDLI Position: Q4 2020 in Review

Renaissance Technologies sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 7,598,131 shares — an estimated $23.9M sold.

Renaissance Technologies first reported a position in PDLI in Q2 2013 and held it in 30 quarters. The position peaked at $125M in Q2 2014. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

Renaissance Technologies reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
Renaissance Technologies sold 7,598,131 PDL BioPharma, Inc. shares in Q4 2020, an estimated $23.9M.
Renaissance Technologies first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 30 quarters.
Renaissance Technologies's PDL BioPharma, Inc. position peaked at $125M in Q2 2014.
33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Renaissance Technologies's 13F filing for Q4 2020, filed 10 Feb 2021.